Pachyonychia Congenita
4
Pipeline Programs
1
Companies
4
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
3
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Palvella TherapeuticsWAYNE, PA
4 programs1
3
PTX-022Phase 31 trial
PTX-022Phase 31 trial
QTORIN 3.9% rapamycin anhydrous gelPhase 31 trial
PTX-022Phase 2/31 trial
Active Trials
+1 more trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Palvella TherapeuticsPTX-022
Palvella TherapeuticsQTORIN 3.9% rapamycin anhydrous gel
Palvella TherapeuticsPTX-022
Palvella TherapeuticsPTX-022
Clinical Trials (4)
A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita
Start: Nov 2022Est. completion: Nov 2023
Phase 3Recruiting
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
Start: Nov 2021Est. completion: Jun 2023
Phase 3Completed
VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita
Start: Sep 2020Est. completion: Dec 2022
Phase 3Completed
Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita
Start: Apr 2019Est. completion: Oct 2020
Phase 2/3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials
1 companies competing in this space